Crystal gazing the new biotechnologies: several scientific, conceptual, and financial challenges face biotechnology if it is to overcome thus far intractable problems in human disease and agriculture

Article Abstract:

Article details a history of progress in controlling disease and utilizing technology in other areas such as agriculture.

Public affairs, Cellular Protein, In-Vitro Diagnostic Substance Manufacturing, Cellular proteins

---

Validating a business model

Article Abstract:

ValiGene S.A. (Paris, France) and Kimeragen (Newtown, PA) have merged under the ValiGen name to offer functional genomics services.

Acquisitions & mergers, Netherlands, Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, France, Brief Article, Kimeragen Inc., ValiGene S.A., ValiGen N.V.

---

Bayer lapse exposes pharma's vulnerability

Article Abstract:

Bayer's withdrawal of its cholesterol reducing drug cerivastatin is problematic for the company, but is also an example of the cracks that are beginning to show in the business of major pharmaceutical companies.

Product standards, safety, & recalls, Germany, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Market information - general, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drugs, Lipotropics & Cholesterol Reducers, Bayer AG, BAYZY

Similar abstracts:

• Abstracts: Dislikes, distastes and the undesired self: conceptualising and exploring the role of the undesired end state in consumer experience
• Abstracts: Information technology as competitive advantage: the role of human, business, and technology resources. Competitive advantage: logical and philosophical considerations
• Abstracts: Self-service technology effectiveness: the role of design features and individual traits. The impact of technology on the quality-value-loyalty chain: a research agenda
• Abstracts: Ethical leadership in insurance and financial services. The gathering storm. Whistle-blowing in the financial services profession
• Abstracts: Biotech companies adapt to big pharma mergers. Genzyme acquires Cell Genesys. Demise of the life science company begins

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.